Instinct Bio named CelSiege representative for IN01 cancer immunotherapy in Japan, China
BIOT•Instinct Bio was appointed CelSiege Biosciences’ non-exclusive authorized representative for IN01 cancer immunotherapy in Japan and China, with any transaction requiring separate negotiations, due diligence and definitive agreements.
1. Representative appointment
Instinct Bio’s authorization, signed Sept. 18, 2026, covers introductions to potential partners, investors, pharmaceutical groups, medical institutions, research organizations and investment funds. Its scope includes facilitating early discussions on licensing, co-development, clinical development, manufacturing and commercialization; any transaction requires separate negotiations, due diligence and definitive agreements.
